Does Anthem (Elevance Health) Cover Methimazole (Tapazole)?

Anthem Formulary Placement for Methimazole

Methimazole appears on Anthem's commercial formularies as a preferred generic medication, which translates to Tier 1 or Tier 2 depending on the specific plan. Generic methimazole is the default covered option; brand-name Tapazole may require a higher copay or a formulary exception request.

Why Generic Tier Placement Matters

Anthem structures its drug formularies using a tiered system where generics occupy the lowest cost-sharing levels. Because methimazole lost patent exclusivity decades ago, virtually all Anthem plans cover the generic formulation with minimal out-of-pocket cost 1. The American Thyroid Association (ATA) identifies methimazole as the preferred first-line antithyroid drug for nearly all patients with Graves hyperthyroidism 2.

How to Verify Your Specific Plan

Formulary placement can shift between Anthem plan types (PPO, HMO, EPO) and between states. Members should log in to anthem.com or call the number on the back of their insurance card to confirm their plan's current formulary. Elevance Health, Anthem's parent company, operates under regional names including Empire BlueCross BlueShield in New York and Wellpoint in California 3. Regardless of regional branding, methimazole coverage policies remain consistent across Anthem-affiliated commercial plans because the drug is classified as medically necessary for hyperthyroidism management per ATA guidelines 2.

Copay Expectations by Tier

Most members pay between $0 and $15 for a 30-day supply of generic methimazole. By comparison, the brand-name Tapazole list price runs approximately $80 per month. Cash-pay pricing without insurance averages roughly $15 per month at major retail pharmacies. Patients with high-deductible health plans (HDHPs) may pay the full negotiated rate until they meet their deductible, though methimazole's low cash price means out-of-pocket exposure remains modest.

Prior Authorization Requirements

Anthem may require prior authorization (PA) for methimazole under certain circumstances. PA difficulty for this medication is generally moderate because methimazole carries a clear FDA indication for hyperthyroidism 1.

When PA Is Triggered

PA requests are most commonly triggered when prescriptions exceed standard dosing thresholds or when the diagnosis code does not align with an FDA-approved indication. Cooper et al. Demonstrated in a landmark New England Journal of Medicine review that methimazole doses of 10 to 30 mg daily control hyperthyroidism in the majority of patients with Graves disease 3. Prescriptions above 40 mg per day or for off-label indications may prompt Anthem's utilization management team to request clinical documentation.

Documentation Your Provider Needs

To satisfy an Anthem PA request, the prescribing clinician should submit thyroid-stimulating hormone (TSH) and free T4 laboratory values confirming hyperthyroidism. The Endocrine Society's clinical practice guidelines recommend measuring TSH, free T4, and total T3 when evaluating thyroid dysfunction 4. Including TSH receptor antibody (TRAb) results strengthens the case for Graves disease specifically 5. Anthem typically processes PA requests within 72 hours for standard requests and 24 hours for urgent requests.

Tips to Reduce PA Delays

Submit labs drawn within the past 90 days. Include a brief clinical note explaining why methimazole is medically necessary over alternatives. Reference the ATA's 2016 guidelines 2, which designate methimazole as first-line therapy for Graves disease. Providers using electronic prior authorization (ePA) through platforms like CoverMyMeds typically receive faster turnaround than fax-based submissions.

Step Therapy Policies

Some Anthem plans enforce step therapy protocols before approving methimazole. This sounds counterintuitive for a first-line drug, but step therapy in this context usually means Anthem wants documentation that the patient has had appropriate diagnostic workup rather than requiring failure of another medication first.

What Step Therapy Looks Like in Practice

Anthem's step therapy for antithyroid drugs typically requires confirmation that the patient has documented hyperthyroidism based on suppressed TSH (below 0.4 mIU/L in most assays) and elevated free T4 or total T3 4. This is not a drug-failure step. It is a diagnostic-confirmation step. The 2016 ATA guidelines emphasize that methimazole should be the initial antithyroid drug for most patients, with propylthiouracil (PTU) reserved for the first trimester of pregnancy or thyroid storm 2.

Propylthiouracil vs. Methimazole

Anthem does not routinely require PTU failure before approving methimazole. In fact, the opposite is true clinically. The FDA issued a boxed warning on PTU in 2010 due to reports of severe hepatotoxicity, including liver failure and death 6. A study published in the Journal of Clinical Endocrinology & Metabolism found that methimazole was associated with fewer adverse hepatic events than PTU across large patient cohorts 7. If an Anthem plan attempts to require PTU trial first, this represents a strong basis for exception.

What Methimazole Costs on Anthem Plans

Out-of-pocket costs depend on the member's specific benefit design. Generic methimazole is one of the least expensive thyroid medications available.

Retail Pharmacy Pricing

At retail pharmacies within Anthem's preferred network, generic methimazole 5 mg or 10 mg tablets cost between $4 and $15 for a 30-day supply. Mail-order pharmacy options through Anthem's pharmacy benefit manager (typically Express Scripts or IngenioRx) may offer 90-day supplies at reduced per-unit pricing. A population-based study in Thyroid journal found that medication cost was a significant predictor of antithyroid drug adherence, reinforcing why low-tier generic placement matters for patient outcomes 8.

High-Deductible Plan Considerations

Members enrolled in Anthem HDHPs paired with health savings accounts (HSAs) pay the negotiated pharmacy rate until reaching their deductible. Because generic methimazole's negotiated rate typically falls between $8 and $18, the financial impact remains low even before the deductible is met. A JAMA Internal Medicine analysis showed that high cost-sharing reduced adherence to chronic medications by 11% to 22%, but this effect was attenuated for drugs priced below $20 per month 9.

How to Appeal an Anthem Denial

If Anthem denies coverage for methimazole, members and providers have a structured appeal pathway. Denials for this medication are uncommon but can occur with off-label use, unusual dosing, or administrative errors.

Internal Appeal Process

Anthem allows one level of internal appeal. The member or prescriber must file the appeal within 180 days of the denial letter. Include the following in every appeal packet: the denial letter with reference number, updated lab results showing hyperthyroidism, a letter of medical necessity from the prescribing endocrinologist or primary care physician, and a citation to the ATA 2016 guidelines recommending methimazole as first-line therapy 2.

External Review Through State IRO

If the internal appeal is unsuccessful, members can request an independent review organization (IRO) review through their state's department of insurance. The IRO decision is binding on Anthem. According to a Government Accountability Office report, approximately 40% to 50% of external appeals for prescription drug denials are overturned 10. Given methimazole's strong guideline support and first-line status, overturn rates for this specific drug are likely higher.

Timeline Expectations

Anthem must issue an internal appeal decision within 30 days for standard appeals and 72 hours for expedited (urgent) appeals. State IRO reviews typically take 30 to 45 additional days. Patients who need methimazole urgently for symptomatic hyperthyroidism should request expedited review and have their physician document clinical urgency, as untreated Graves disease carries risks including thyroid storm, atrial fibrillation, and osteoporosis 11.

Clinical Context: Why Anthem Covers Methimazole

Anthem's coverage of methimazole aligns with overwhelming clinical evidence supporting its use as first-line treatment for hyperthyroidism.

Graves Disease Treatment Standards

Graves disease accounts for 60% to 80% of hyperthyroidism cases in iodine-sufficient regions 3. Methimazole works by inhibiting thyroid peroxidase, the enzyme responsible for iodination of tyrosine residues on thyroglobulin. A randomized trial published in the Journal of Clinical Endocrinology & Metabolism found that methimazole 15 mg daily achieved euthyroidism in 86% of Graves disease patients within 6 weeks 12.

Long-Term Remission Data

Approximately 40% to 50% of patients treated with methimazole for 12 to 18 months achieve long-term remission after drug discontinuation 13. The GREAT (Graves Recurrence Events After Therapy) score uses clinical variables including age, free T4, TRAb titer, and goiter size to predict which patients are most likely to remain in remission 14. Anthem's coverage policy reflects the drug's role as both a definitive treatment option and a bridge to radioactive iodine ablation or thyroidectomy.

Monitoring Requirements During Treatment

The ATA recommends monitoring liver function tests and complete blood count before initiating methimazole 2. Agranulocytosis, the most serious adverse effect, occurs in approximately 0.2% to 0.5% of patients and is dose-dependent 15. Thyroid function should be checked every 4 to 6 weeks during dose titration. These monitoring visits are typically covered under Anthem's preventive or diagnostic lab benefits, adding minimal additional cost for the patient.

Special Situations and Exceptions

Pregnancy and Methimazole

Methimazole carries an FDA pregnancy category D rating due to teratogenic effects including aplasia cutis and choanal atresia observed in the first trimester 6. The ATA recommends switching to PTU during the first trimester, then transitioning back to methimazole after week 16 2. Anthem covers both methimazole and PTU, so this therapeutic switch does not create a coverage gap.

Pediatric Coverage

Methimazole is FDA-approved for pediatric use and is the recommended antithyroid drug for children and adolescents with Graves disease 16. Anthem plans covering dependents will include methimazole under the same formulary tier as adult coverage. Pediatric dosing typically starts at 0.2 to 0.5 mg/kg/day.

Medicare Advantage Plans Through Anthem

Anthem Medicare Advantage plans cover methimazole under Part D pharmacy benefits. Tier placement on Medicare Advantage formularies mirrors commercial plans, with generic methimazole on Tier 1. Members in the coverage gap (donut hole) still benefit from the 75% manufacturer discount on brand-name drugs, though generic methimazole pricing makes the gap nearly irrelevant for this medication. The Centers for Medicare & Medicaid Services requires all Part D plans to cover at least one drug in each therapeutic class, and methimazole fulfills the antithyroid category 17.